CIK 0001770121
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Sana Biotechnology, Inc.
Sign in to watch- Ticker
- SANA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831381173
- Phone
- +1 206-701-7914
- Business address
- 188 EAST BLAINE STREET, SUITE 350, SEATTLE, WA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-04 | REICIN ALISE Director | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2025-06-05 | REICIN ALISE Director | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2024-06-06 | REICIN ALISE Director | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2024-06-06 | REICIN ALISE Director | Grant or award · Stock Option (Right to Buy) | +54,278 | 54,278 | ||
| 2023-06-08 | REICIN ALISE Director | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2022-06-06 | REICIN ALISE Director | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2021-02-03 | REICIN ALISE Director | Grant or award · Stock Option (Right to Buy) | +11,795 | 11,795 | ||
| 2021-02-03 | REICIN ALISE Director | Grant or award · Stock Option (Right to Buy) | +7,000 | 7,000 |
Page 1 of 1 · 8 trades